||EPS - Basic
||Market Cap (m)
Real-Time news about Vindon H. (London Stock Exchange): 0 recent articles
|masurenguy: Secular decline in profit continues at the interims. Looks like they are on a current year PER of circa 13.5 so the share price could still potentially decline by a further 20% to 25% from current levels.|
|sagem: What news is expected and what do we want to push the share price up|
|masurenguy: daicaprice - 23 Apr'10 - 64: Hi Pete et all, is there life in the old dog? Am still holding but they've dropped off my watch list cos it's been so long, anyone reckon it's worth an average down?
Since the only response to you question is just the very unhelpful and blunt retort of "DYOR" I thought that I would provide you with my current view !
Sales of £5.5m and eps of 0.94p puts them on an historic PER of 12 which is not cheap for a very small cap in this climate. Net debt of £2m and cash of just over £200K means that there is always a chance of further dilution via another fund raising in spite of a positive cashflow. The current EV is circa £12m which is more than twice annual sales and overvalued in my opinion.
The AIM index is up by around 50% over the past 14 months since the current rally began but in contrast VDN is down 48% over the same timeframe from 21p to 11p. Nevertheless, Vindon still appears to be overvalued on comparative metrics in my opinion and on a trailing PER of 8 the share price would be around 7.5p which might be a more realistic level. You should carefully consider your own valuation equation before any further thoughts of potentially averaging down at this point in time.|
|masurenguy: Except that the share price has been on a downward track for the past 6 months having fallen by 50% during that period. Good call by Rivaldo last August.
rivaldo - 17 Aug'09 - 72: Hi Mas. Been in and out of VDN myself in the past. Good company, but has always been on a high rating and looks overpriced now imho. The company broker's note dated 10th August is apparently now forecasting just 0.8p EPS this year and the same 0.8p EPS next year. A P/E of 20.6 is far too high - and VDN also has around £2.4m net borrowings. It's difficult to justify a share price of more than 10p for a company showing no growth and with material net borrowings, and maybe even 6p-8p is more appropriate.
Even after falling from 19p to 9.5p in that 6 month timeframe, the current year PER is still in the region of 12 or 13 which is not cheap for a small cap in this market !|
|masurenguy: Still overvalued in my opinion with a prospective current year PER of circa 14 which is expensive for a small cap in this market. A current year PER of circa 7 or 8 would price them around 6p, which Rivaldo suggested could be fair value back in August when the price was around 17p. The most recent share sale price was 10.5p so there could still be further downside to come. The share price here has not only missed the whole market rally this year but has actually dropped by 45% since the end of June.
Very glad that I didn't invest here when I first began to check them out in May. I subsequently bought into Cryo-Save instead, who are the market leader in stem cell storage. In contrast with VDN, their share price is up by 75% over the past 4 months !|
|masurenguy: Still slip sliding away. Looks like your 10p valuation might even be achieved Riv ! Even at that price they're probably on a current year PE of around 9, which is still not cheap for a company where sales are flatlining and earnings are falling.
The VDN share price has now dropped by almost 35% during the past 3 months, going in an opposite direction to the market rally during that period.|
|masurenguy: rivaldo - 17 Aug'09 - 22:23 - 72 of 72: A P/E of 20.6 is far too high - and VDN also has around £2.4m net borrowings. It's difficult to justify a share price of more than 10p for a company showing no growth and with material net borrowings, and maybe even 6p-8p is more appropriate.
Riv - I think that you're probably right - looks very overpriced. In the meantime I bought into Cryo-Save circa 3 weeks ago and their share price has since gone up by more than 50% following their announced intention to list on Euronext.|
|rivaldo: Hi Mas. Been in and out of VDN myself in the past. Good company, but has always been on a high rating and looks overpriced now imho.
The company broker's note dated 10th August is apparently now forecasting just 0.8p EPS this year and the same 0.8p EPS next year. A P/E of 20.6 is far too high - and VDN also has around £2.4m net borrowings.
It's difficult to justify a share price of more than 10p for a company showing no growth and with material net borrowings, and maybe even 6p-8p is more appropriate.|
|dealit: shooting star, bought these as you did shortly before results, did some research felt results would be good and they were. In saying that the share price dropped back today someone sold 100000 late Tuesday not to concerned as I have decided to keep these in my portfolio. As for share tipping, research companies with results due out pick the once with good trading statements and no bad news check the charts and make sure the share price is down and buy a day or so before the results are announced. I have done well of late with ams, pts both rising 20% I then sell and move on. BE LUCKY|
|dealit: Good set of results today, I have only just bought into Vindon my research was positive. They seem to have a niche market product paying dividends at this stage of there development is very encouraging. I do feel they are news shy which may be holding the share price back, long term hold I feel with a steady dividend income.|
Vindon Healthcare share price data is direct from the London Stock Exchange